

2019-nCoV Spike protein RBD (L452R)

Catalog No: C19SD-G235H

A new SARS-CoV-2 variant identified in California termed as 20C/S:452R or CAL.20C, possesses L452R as one of the three mutations in the spike protein and this mutation could affect the binding of certain therapeutic monoclonal antibodies. As new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization. SignalChem's Recombinant 2019-nCoV Spike protein S1 subunit, receptor-binding domain (RBD) (319-541) (L452R) was expressed in CHO cells using a C-terminal his tag.

Unique Selling Points




Fully Functional Protein




Strong binding affinity to hACE2



Activity determined by functional ELISA



Effective for Neutralizing antibody research



Competitors



Applications



COVID19 ELISAs



Diagnostic kits R&D



COVID19 Protein Arrays



Recombinant antibody production



Western Blot